Liechtenstein

A pilot trial of the swissdamed database – an initiative designed to mirror the EU’s Eudamed – was successfully completed in June, allowing the regulator Swissmedic to confirm live implementation in January 2024. Work on two swissdamed modules is underway.

With CHF20 million (£12.4 million) under its belt from two new financings, Liechtenstein-based Pantec Biosolutions is gearing up for two Phase II clinical trials with hormone-based IVF therapies, to be delivered using transdermal patches in conjunction with the company's PLEASE (Painless Laser EpidermAl System) technology.

The Liechtenstein-based drug delivery company Pantec Biosolutions has expanded its scientific advisory board to include Professor Rox Anderson, Dr Jean-Luc Levy and Professor Robert Strohal. Dr Anderson is a professor at Harvard Medical School, an adjunct professor at Massachusetts Institute of Technology and director of the Wellman Center for Photomedicine at Massachusetts General Hospital; Dr Levy has more than 20 years' experience in the field of health technology, specifically for laser application in dermatology and cosmetology; and Dr Strohal is associate professor and head of the department of dermatology and venerology at the Federal University Teaching Hospital Feldkirch, Austria.